Genetic variations can influence how individuals respond to CFTR modulators, impacting both efficacy and toxicity. Pharmacogenomics plays a vital role in personalizing treatment, as certain mutations in the CFTR gene respond better to specific modulators. Additionally, genetic differences in drug-metabolizing enzymes can affect drug clearance and the risk of toxic effects, underscoring the importance of personalized medicine in toxicology.
